REDONDO BEACH, CA / ACCESSWIRE / July 21, 2015 / Diabetes affects approximately 387 million people worldwide and that figure is expected to soar to nearly 600 million by 2035, according to the International Diabetes Federation. At the same time, global health expenditures tied to diabetes are expected to surge to nearly a half billion dollars over the coming years, as the world’s population ages and puts an increasingly large burden on healthcare systems to cover the costs of treatment.

In this article, we’ll take a look at Cell MedX Corp. (OTC: CMXC) and its radically different approach to diabetes treatment that could create an entirely new category in the space.

Patient Zero

In 2014, Cell MedX acquired the rights to key proprietary microcurrent technology targeting the treatment of diabetes and related ailments from co-developers Jean Arnett and Bradley Hargreaves. As a sufferer of Type 1 diabetes herself for more than 40 years, Ms. Arnett had been experimenting with the technology to gauge its safety and efficacy profile firsthand and the team quickly came to realize its tremendous potential within the market.

Click To Sign Up For Future Email Updates On Cell MedX Corp.

As patient zero for the new technology, Ms. Arnett reported A1C levels that fell from 10.7 to 7.6 and insulin sensitivity levels that increased 60%. These significant developments enabled her to cut her insulin requirements in half, while realizing additional benefits like lower blood pressure, less diabetic neuropathy, and fewer diabetic wound issues. In addition, these benefits were realized without any apparent negative side-effects.

While a single patient certainly doesn’t prove anything from a rigorous scientific perspective, Ms. Arnett’s experience does show an extraordinary degree of personal commitment, dedication and belief in the technology, which is truly an invaluable consideration among the executive officers and directors of a public company. The initial data also instills confidence – especially in terms of a safety profile – when compared to completely untested technologies that offer theoretical solutions, but may be years and millions of dollars away from human trials.

Improving Efficacy

Cell MedX’s eBalance technology represents a major departure from current approaches to diabetes treatment. Given that there hasn’t been any really new diabetes treatment developed since the creation of insulin, and that virtually all diabetes sufferers rely on extremely frequent injections of the drug, Cell MedX appears to be poised to positively impact individual dosage requirements while improving overall outcomes of insulin-based treatment protocols.

By using physical energy to alter metabolic pathways, the Cell MedX eBalance technology is reported to affect changes in blood sugar disposition which has so far shown to measurably enhance existing treatments. Currently, the technology is being applied for just 20 minutes three times weekly to demonstrate the onset of positive effects.

As a result of the preliminary trials and in relatively short order since its founding, Company management recently announced the commencement of a series of clinical trials aimed at moving the technology ahead in order to realize their ambitious quest for an affordable and readily available medical device designed specifically for home care use as part of the Company’s ultimate commercialization strategy.

Watch a Q&A video with CMXC CEO Frank McEnulty and Chief Medical Officer John Sanderson, MD

By contrast, most new approaches in the diabetes sector are focused exclusively pharmaceutical solutions aimed at making insulin delivery less reliant on injections. MannKind Corporation (NASDAQ: MNKD) has reached a $2.2 billion valuation due in large part to its Afrezza technology – an inhaled insulin used to control high blood sugar. Novo Nordisk A/S (NYSE: NVO) has also introduced an easy-to-use insulin tablet, although the product only accounts for a small fraction of its $121 billion market capitalization.

In the small-cap space, Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) is working on an orally ingestible insulin capsule that’s in Phase II clinical trials, taking the same approach to insulin delivery as many larger competitors. Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) is taking a bit of a different approach with its dual inhibitor of sodium-glucose transporters 1 and 2, with plans to initiate clinical trials this year targeting Type 1 diabetes.

Fast & Low-Cost

Cell MedX has already started recruiting 30 Type 1 and Type 2 diabetic patients for its Phase II-A clinical trial in Orange County, California. Over the next six to eight months, the company medical team will carefully study clinical endpoints including the reduction in HbA1C levels independent of other factors. The clinical trials will also continue to assess how metabolic changes and pathways lead to improved glycemic control and to determine optimal parameters and settings for the technology.

At the same time, management is working on early stage steps towards the development of a commercially practicable prototype device for use in subsequent trials. The prototype would include refined electronic circuitry, hardware and software optimized to the most effective parameters. Preliminary design considerations are focused with the user in mind in order to simplify, mobilize, and create a pleasurable user experience based on ease of use and convenience.

The company’s experience with the technology to-date suggests that it has a robust safety profile that could translate to rapid industry approval. Unlike the pharmaceutical cousins mentioned earlier in the article, this adjunct technology won’t require millions of dollars and decades of trials to achieve a market launch target date, as so-called 510(k) devices are often approved at a fraction of the cost and time than pharmaceutical drugs.

Looking Ahead

Cell MedX has an exciting future ahead as it brings its innovative eBalance technology into the design, development, trial and prototyping pathway towards industry approval and market launch. With its upcoming clinical trials underway, investors can expect to see a steady stream of potentially market-moving news, while all early indications are pointing to robust efficacy and safety profiles that suggest these trials hold the potential to offer diabetes sufferers an entirely new class of treatment. And with a focus on diabetes, there is no shortage of demand for an alternative solution to what is a seemingly endless growth market.

For more information, visit the company’s website at www.cellmedx.com.

Click To Sign Up For Future Email Updates On Cell MedX Corp.

http://www.tdmfinancial.com/emailassets/cmxc/cmxc_landing.php

Legal Disclaimer:

Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit: http://secfilings.com/Disclaimer.aspx.

SOURCE: Emerging Growth LLC

ReleaseID: 430715

STUTTGART, GERMANY / ACCESSWIRE / July 21, 2015 / Medicus Homecare Inc. (PINKSHEETS: MDCRE) (the “Company“) is pleased to announce that it will open the first of seven new care centers in Nuremberg, Germany.

The new 3500 square foot center is currently being outfitted with the necessary equipment and is scheduled to open in September 2015. The Company is also currently in the process of securing the necessary staff needed in order to service the expected patients. The total time from securing the location to full operational status will be approximately three months.

The facility will have six transitional rooms and beds while being able to service up to thirty in-home care patients. The facility is designed as a transitional center where long term care patients are transferred in from current hospital care. The patients will normally stay in the center on average for a week while specialized care aids design a specific in-home care plan tailored to the needs of each patient. The patients are then transferred to their own homes where they will be provided with twenty-four hour a day in-home care.

Due to strong demand for in-home care services in the region, the Company expects the new center to reach full capacity within the next twelve months with the addition of twenty five to thirty new patients. This would be the equivalent of the patient load at the Company’s current Stuttgart location.

“Our growth plan for the next twenty four months has always included the opening of seven new care centers that would service a minimum of twenty-five patients each. These locations include; Nuremberg, Munich, Frankfurt, Aachen, Heidelberg, Karlsruhe and Wuerzburg,” commented Dr. Karahodza. “Today I am proud to announce the opening in September of the first of these new locations in the city of Nuremberg, Germany. The opening of this new location gives us the ability to double our current patient capacity instantly while filling the strong need for specialized in-home patient care in the area. Our goal is to open one new location per quarter thereby increasing our patient capacity by twenty-five to thirty patients per quarter. With today’s announcement I can say we are firmly on track to achieve our goals.”

The Company is also pleased to announce that it is currently in negotiations for a second new location in another major German city. Negotiations are ongoing and a news release will be issued once the location has been secured.

ABOUT MEDICUS HOMECARE INC.

The Company offers medical in-home care services in Germany including ventilation for patients that suffer from debilitating diseases such as Amyotrophic Lateral Sclerosis (ALS), Muscular Dystrophy (MD), Guillain-Barre syndrome (GBS), and Chronic Obstructive Pulmonary Disease (COPD). Other services provided by the Company include acute post-patient care, respiration optimization and monitoring of long-term home respiration.

For additional information regarding the Company, please visit www.medicushomecareinc.com, email info@medicus-24.de, or telephone +49 157 894 69537.

On behalf of the Board,

Dr. Orhan Karahodza
President

Notice Regarding Forward-Looking Statements

This press release contains “forward-looking statements,” as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future.

Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with intellectual property protection, marketing and sale, manufacturing and distribution and difficulties associated with obtaining financing on acceptable terms. We are not in control of healthcare trends and prices and these could vary to make our business development uneconomic. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our most recent annual report for our last fiscal year, our quarterly reports, and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

SOURCE: Medicus Homecare Inc.

ReleaseID: 430727

VANCOUVER, BC / ACCESSWIRE / July 21, 2015 / Canarc Resource Corp. (TSX: CCM, OTCQB: CRCUF, Frankfurt: CAN; “Canarc”) announces positive metallurgical test results for recovering gold from a high-grade gold concentrate sample produced from the New Polaris gold mine project (“New Polaris”).

The results from the recently completed first stage Albion Process metallurgical test work indicate that gold recoveries of approximately 85% can be achieved without modification to the existing PanTerra Gold Limited (“Panterra”) Las Lagunas Albion/CIL process plant.

Update On Stage One Activities

Albion Testing

– Oxidation test work on the finely ground New Polaris concentrate indicated gold recoveries of approximately 85% can be achieved using the Albion process.
– Albion testing will now enter into a second, final phase aimed at further optimizing the test conditions for improving recoveries and determining economic parameters.

Environmental Permitting

– Canarc is collecting baseline environmental data for the New Polaris site.
– Canarc entered into the BC Environmental Assessment pre-application phase in July 2015.
– Canarc met with the Taku River Tlingit First Nation in June 2015 to consult on and review the planned activities for advancing the New Polaris property.
– Canarc has submitted a Notice of Work for an in-fill drilling program at New Polaris and is awaiting receipt of a permit from the BC Government. The in-fill drilling program is set to begin in the 3rd quarter 2015 as part of Phase 2 of the Agreement with Panterra Gold.

Funding

– Canarc has received a total of C$500,000 from PanTerra to date. These funds are sufficient to complete all the activities contemplated under stage one of the Agreement.

Mine Engineering

– Engineering work confirms that it is technically feasible to produce approximately 120,000 ounces of gold in concentrate annually at New Polaris.

Next Steps

– Upon the satisfactory completion of the Phase 1 technical and economic review of the New Polaris project by Panterra Gold, expected by late July, PanTerra will have 60 days to elect to fund the C$3.5 million Phase 2 work program. The Phase 2 program includes in-fill drilling, mine planning, environmental sampling and permitting.

Catalin Chiloflischi, CEO of Canarc, remarked: “We are pleased that phase one of the metallurgical test-work confirmed that recovery of approximately 85% of the gold is possible from New Polaris concentrate using the Albion Process. This is a major step forward in advancing the New Polaris Gold mine to feasibility and production.”

About the Albion Process and Panterra Gold

The Albion Process

– The Albion Process was developed in 1994 by Glencore and is patented worldwide.
– The process is a combination of ultrafine grinding and oxidative leaching at atmospheric pressure.
– The feed to the Albion Process are base or precious metal sulfide concentrates.
– The sulphides in the feed are oxidized, allowing the desired metals to be recovered by conventional means.
– There are three Albion Process plants currently in operation. Two plants treat a zinc sulphide concentrate and are located in Spain and Germany. A third Albion Process plant is operated by Panterra in the Dominican Republic treating a refractory gold/silver concentrate. A fourth plant is under construction in Armenia, and will be treating refractory gold.
– Additional Information about the Albion Process can be found online at: http://www.albionprocess.com/EN/Pages/default.aspx

Panterra Gold

– Panterra is an Australian listed gold and silver producer. Panterra’s core project is the 100% owned Las Lagunas gold/silver tailings retreatment project that processes historic tailings from the the Pueblo Viejo mine in the Dominican Republic.
– As Panterra is searching for a long term supply of refractory gold concentrate, the remaining life for the existing tailings in Dominican Republic is expected to match well with New Polaris anticipated timeline to production.

Garry Biles, P.Eng, Canarc’s President and COO, is the Qualified Person who reviewed and approved the technical information contained in this news release.

An NI 43-101 preliminary economic assessment report (“PEA”) for the New Polaris gold mine project, dated April 10, 2011, was completed by Moose Mountain Technical Services. A copy of the report was filed on the Sedar website on May 26, 2011 and can be viewed at: http://www.sedar.com.

“Catalin Chiloflischi”
____________________
Catalin Chiloflischi, CEO

CANARC RESOURCE CORP.

FOR MORE INFORMATION:

Catalin Chiloflischi, CEO
Toll Free: 1-877-684-9700 Tel: (604) 685-9700 Fax: (604) 685-9744
Email: info@canarc.net Website: www.canarc.net

About Canarc Resource Corp. Canarc is a growth-oriented, gold exploration and mining company listed on the TSX (CCM) and the OTC-BB (CRCUF). The Company is currently focused on exploring its gold properties in north and central BC. Canarc is also seeking a partner to advance its 1.1 million oz, high grade, underground, New Polaris gold mine project in British Columbia to the feasibility stage. Canarc is also seeking to acquire an operating or pre-production gold mine in the Americas.

FORWARD-LOOKING AND CAUTIONARY STATEMENTS

The Preliminary Economic Assessment is preliminary in nature, it includes inferred resources that are considered too speculative geologically to have economic considerations applied to them that would enable them to be categorized as mineral reserves and there is no certainty that the preliminary economic assessment will be realized. Mineral resources that are not mineral reserves do not have demonstrated economic viability.

This news release contains “forward-looking statements” within the meaning of the United States private securities litigation reform act of 1995 and “forward-looking information” within the meaning of applicable Canadian securities legislation. Such forward looking statements and information herein include, but are not limited to, statements regarding Canarc’s future performance, including anticipated acquisitions, exploration, development, production, revenues, cash costs, capital costs, timing and expenditures to develop new mines and mineralized zones, gold grades and recoveries, and the use of the Company’s working capital. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “intends” or “anticipates,” or variations of such words and phrases or statements that certain actions, events or results “may,” “could,” “should,” “would” or “occur.” Forward-looking statements are based on the opinions and estimates of management as of the date such statements are made and they are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including: the receipt of all necessary approvals; uncertainty of future production, capital expenditures and other costs; financing and additional capital requirements; the receipt in a timely fashion of any further permitting for the New Polaris Gold Project; legislative, political, social or economic developments in the jurisdictions in which the Company carries on business; operating or technical difficulties in connection with mining or development activities; and the risks normally involved in the exploration, development and mining business. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward looking information. The Company does not intend to, and does not assume any obligation to update such forward-looking statements or information, other than as required by applicable law.

SOURCE: Canarc Resource Corp.

ReleaseID: 430716

NEW YORK, NY / ACCESSWIRE / July 21, 2015 / Paragon Shipping Inc. (NASDAQ: PRGN) a global shipping transportation company specializing in drybulk cargoes, recently reported first quarter 2015 financial results. The highlights of the report include revenue falling year over year to $10.03 million, and net loss going deep in the red to a loss of $8.93 million. The company has struggled as a result of a struggling resource market and the credit crisis in Greece.

Paragon is based in Greece and with implications of new taxes and the withdrawal of special tax breaks on the horizon; the company is faced with a tough decision. Remaining in Greece will bring on unexpected rises in taxes and push net losses further into the red. On the other hand, costs of relocating the company’s headquarters can prove to be unaffordable by the company.

For a more detailed research report that discusses the best course of action for investors and analyst recommendation on Paragon Shipping Inc. please follow the link. There is no cost obligation required to view analyst brief.

http://bit.ly/-PRGN_AnalystReport

About Broad Street Alerts

We make the connection between sophisticated investors and high quality micro and small cap companies. An issuer of reports that provide a straightforward assessment of the profiled company. They include stocks traded in the NYSE, NASDAQ, and OTCBB exchanges.

Safe Harbor Statement

This press release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to anticipated revenues, expenses, earnings, operating cash flows, the outlook for markets and the demand for products. Forward-looking statements are no guarantees of future performance and are inherently subject to uncertainties and other factors which could cause actual results to differ materially from the forward-looking statements. Such statements are based upon, among other things, assumptions made by, and information currently available to, management, including management’s own knowledge and assessment of the Company’s industry and competition. The Company refers interested persons to its most recent Annual Report on Form 10-K and its other SEC filings for a description of additional uncertainties and factors, which may affect forward-looking statements. The company assumes no duty to update its forward-looking statements

Compliance Procedure

Content is researched, written and reviewed on a best-effort basis by a 3rd party research analyst. However, we are only human and may make mistakes. This report was prepared for informational purposes only. A full disclaimer can be found by viewing the full analyst report. We do not hold any positions and have not been compensated in any form for this press release and coinciding reports. For more information and services provided beyond this press release please use contact information provided below. If you notice any errors or omissions, please notify us.

Contact:
editor@broadstreetalerts.com

SOURCE: Broad Street Alerts

ReleaseID: 430720

VANCOUVER, BC / ACCESSWIRE / July 21, 2015 / CIBT Education Group Inc. (TSX: MBA, OCTQX International: MBAIF) (“CIBT”) is pleased to report that it has closed its previously announced non-brokered private placement (the “Financing”) raising gross proceeds of $1,224,250 by the issuance of 4,897,000 units (each a “Unit”) at a price of $0.25 per Unit. Each Unit consists of one common share and one-half of one common share purchase warrant (each a “Warrant”). Each Warrant entitles the holder thereof to purchase one additional common share of the company at a price of $0.30 per share for a period of 24 months from the closing date.

“We are pleased to see the response to this latest private placement,” commented Toby Chu, President and CEO, Vice Chairman of CIBT Education Group Inc. “In mid-April, CIBT re-initiated its investor relations campaign by conducting a series of road shows and re-introducing the company and its exciting business activities to the investment community. After nearly six years of conducting a very low level of investor relations activities while growing our business, we were excited to learn that there is substantial interest in CIBT’s innovative business model and prudent management approach. Many new investors have purchased our shares from the open market directly as a result of our renewed investor relations campaign, and our share trading volume increased significantly with over 9.78 million shares traded during the past 100 days. CIBT’s trading price has also increased progressively from its 3 month low of $0.22 to the high of $0.34. It is our ongoing intention to maintain a manageable share structure with minimal dilution at each equity raise. We thank our shareholders for their interest and support.”

Finder’s fees were paid in connection with the Financing. All of the securities issued in the Financing are subject to a statutory hold period expiring November 20, 2015. The net proceeds from the Financing will be used by the company for operations and general working capital.

About CIBT Education Group:

CIBT Education Group Inc. is an education management company focused on the global education market since 1994. Listed in Canada on the Toronto Stock Exchange and in the U.S. on the OTCQX International, CIBT owns and operates a network of business, technical and language colleges in North America and Asia. CIBT offers cooperative joint programs in 12 countries with campuses, recruitment offices and training centers enrolling over 7,000 students annually. Its education business is operated through Sprott Shaw College (established in 1903), Acsenda School of Management, CIBT School of Business China, and Global Education Alliance Recruitment Centers in China and other overseas countries. Through these subsidiaries, CIBT offers recognized and approved business and management degrees, programs in college preparation, healthcare, hotel management and tourism, English language training, English Teacher Certifications, junior and high school preparation programs for overseas study, and other career/vocational training. CIBT also owns Irix Design Group, a leading design and advertising company based in Vancouver, Canada, Global Education Alliance (“GEA”) and Global Education City Holdings Inc. (“GEC”). GEA recruits international students for many elite kindergarten, primary, secondary schools and universities in North America. GEC is an investment holding and management company with a special focus on education related real estate projects in Canada. Visit us online at www.cibt.net.

For more information contact:

Toby Chu
Vice-Chairman, President & CEO
CIBT Education Group Inc.
Investor Relations Contact: 1-604-871-9909 extension 318 or | Email: info@cibt.net

SOURCE: CIBT Education Group Inc.

ReleaseID: 430718